Replies to post #1091 on Arbutus Biopharma Corporation (ABUS)

[BoilerRoom]

ZMAPP is only effective the first couple daysthe host is exposed to Ebola. Works like an aspirin to a toothache temporarily pain reliever.

[samana maker]

They will make more u know that

[MinnieM]

There is very little zmapp left. Plus, they will have to go through the same regulatory issues as TKMR with the FDA. Odds are high both companies will end up as experimental treatments in Africa, but, TKMR has a good chance of being first.

Plus, we can't tell from just two patients whether or not these antibodies worked. 55% have died from the current outbreak and those with supportive care have usually done the best. The two that were treated most likely have better immune systems than those living in the outbreak sites in Africa. Better immune systems coupled with better supportive care make a difference in itself. Again, we don't have enough data to know whether or not this drug actually made a difference. I hope it did since we need a cure, but, we simply don't know yet.

Please stick to facts.

Directly from the company that makes zmapp:
http://www.mappbio.com/zmapinfo.pdf

ZMappTM was first identified as a drug candidate in 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available.

In Reply to 'legalizeMJ'
WRONG ! WRONG ! WRONG !

There are plenty of supply of ZMAPP ,enough for AT LEAT 10,000. people or more. TKMR is no longer needed.

Therefore, TMKR will get a problem here, big problem !!!!!

(cnn news 8/10)